Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of April 2014. The registrant is a foreign private issuer based in Petach-Tikva, Israel, focused on biopharmaceutical development.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a financial statement.
Material Changes
On April 29, 2014, the company submitted a protocol to the U.S. Food and Drug Administration (FDA) for a Phase II clinical trial of its drug candidate CF102. The trial is intended for the treatment of advanced liver cancer.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a detailed discussion of risks and contingencies beyond the context of the clinical trial submission. No unusual items were reported in this document.
Investor Verification Checklist
- Verify the FDA's acceptance of the Phase II clinical trial protocol for CF102.
- Review the full text of the press release (Exhibit 99.1) for specific trial design details.
- Monitor subsequent filings for updates on the trial initiation timeline.
- Check the company's most recent Form 20-F for current financial position and cash runway.